Akebia Therapeutics, Inc.
AKBA
$1.58
$0.010.64%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.77M | 62.47M | 57.34M | 46.50M | 37.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.77M | 62.47M | 57.34M | 46.50M | 37.43M |
| Cost of Revenue | 10.28M | 10.72M | 8.16M | 8.13M | 5.92M |
| Gross Profit | 48.49M | 51.76M | 49.17M | 38.37M | 31.51M |
| SG&A Expenses | 29.09M | 26.56M | 25.74M | 27.68M | 26.52M |
| Depreciation & Amortization | -- | -- | -- | 9.01M | 9.01M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.32M | 48.28M | 43.66M | 56.60M | 49.93M |
| Operating Income | 4.45M | 14.19M | 13.68M | -10.10M | -12.51M |
| Income Before Tax | 1.16M | 247.00K | 6.11M | -22.80M | -20.04M |
| Income Tax Expenses | 615.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | 540.00K | 247.00K | 6.11M | -22.80M | -20.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 540.00K | 247.00K | 6.11M | -22.80M | -20.04M |
| EBIT | 4.45M | 14.19M | 13.68M | -10.10M | -12.51M |
| EBITDA | 4.77M | 14.51M | 13.99M | -754.00K | -3.13M |
| EPS Basic | 0.00 | 0.00 | 0.03 | -0.10 | -0.10 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.02 | -0.05 | -0.06 |
| EPS Diluted | 0.00 | 0.00 | 0.03 | -0.10 | -0.10 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.02 | -0.05 | -0.06 |
| Average Basic Shares Outstanding | 264.79M | 262.57M | 235.50M | 218.70M | 210.35M |
| Average Diluted Shares Outstanding | 274.37M | 271.10M | 241.60M | 218.70M | 210.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |